GSK241206C40000
- 0.05
- 0.000.00%
GlaxoSmithKline Newsroom
First Single-dose Medicine for P. Vivax Malaria Prequalified by WHO and Included in WHO Guidelines
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
Marjorie Taylor Greene Discloses Buys of AMD, Alphabet, Microsoft, Others
Berenberg Lowers Price Target on GSK to GBP16 From GBP18.20, Maintains Buy Rating
Berenberg Bank Keeps Their Buy Rating on GlaxoSmithKline (GSK)
UK Shares Tick Up as Market Watchers Await Key US Inflation Data
European Commission Approves Products by BeiGene, GSK and Novartis
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Express News | GSK's Fully Liquid Menveo Meningococcal Vaccine Approved By European Commission
GSK's Liquid Meningitis Vaccine Gets EU Authorization
Bird Flu Found In Raw Milk Leads To Recall In California
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
FDA Accepts GSK's BLA for Blenrep Combos in Multiple Myeloma
Optimistic Buy Rating for GlaxoSmithKline: Undervalued Stock With Promising Growth Prospects
Goldman Sachs Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
GSK Cancer Therapy Candidate Accepted for FDA Review
Blenrep Combinations Accepted for Review by the US FDA for the Treatment of Relapsed/refractory Multiple Myeloma
GSK's RSV Vaccine Approved for Japanese Patients in Their 50s
Arexvy Approval Expanded to Adults Aged 50-59 at Increased Risk of Severe RSV Disease in Japan
Optimism Over Global Healthcare Sector Rises: Jefferies